Innovative therapeutics

Investors

Press Releases

Advanced Search
  • Aug 23, 2005

    BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Jeffrey Cooper has been promoted to the position of Chief Financial Officer, effective immediately. Mr. Cooper succeeds...

  • Aug 1, 2005
    Conference Call and Webcast to Be Held Tuesday, August 2, at 12:00 p.m. EDT (18:00 CEST)

    BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced results for its second quarter ended June 30, 2005. The net loss was $21.3 million ($0.33 per share) for the second quarter of...

  • Aug 1, 2005

    BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration for Orapred ODT(TM) (prednisolone sodium...

  • Jul 14, 2005
    $59.9 Million of Common Stock Priced

    BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that it plans to publicly offer 8,500,000 shares of its common stock, pursuant to an effective shelf registration statement. In...

  • Jul 5, 2005
    - New Top Line 2005 Product Revenue Guidance Issued -

    BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that it has eliminated 58 positions, of which 52 were held by personnel responsible for the sale of Orapred(R) (prednisolone...


BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS

Products

Palynziq™
Brineura™
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information